Holen Sie sich die Stockscreener-App
130.15
2.11%
-2.81
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MASI?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$132.96
Offen:
$133.33
24-Stunden-Volumen:
843.87K
Relative Volume:
1.14
Marktkapitalisierung:
$6.99B
Einnahmen:
$1.97B
Nettoeinkommen (Verlust:
$-494.50M
KGV:
-14.12
EPS:
-9.22
Netto-Cashflow:
$137.20M
1W Leistung:
-6.47%
1M Leistung:
+0.25%
6M Leistung:
-16.55%
1J Leistung:
-27.53%
1-Tages-Spanne:
$129.21
$133.82
1-Wochen-Bereich:
$129.21
$139.22
52-Wochen-Spanne:
$125.94
$194.88
Masimo Corp Stock (MASI) Company Profile
Firmenname
Masimo Corp
Sektor
Branche
Telefon
949-297-7000
Adresse
52 DISCOVERY, IRVINE, CA
Compare MASI vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MASI
Masimo Corp
|
130.15 | 7.14B | 1.97B | -494.50M | 137.20M | -9.22 |
|
ABT
Abbott Laboratories
|
112.68 | 193.83B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
366.05 | 140.01B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
99.49 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.73 | 109.92B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
75.87 | 44.36B | 6.07B | 1.06B | 799.60M | 1.8527 |
Masimo Corp Stock (MASI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-17 | Eingeleitet | BofA Securities | Neutral |
| 2024-12-27 | Bestätigt | Raymond James | Outperform |
| 2024-11-06 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-06-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-15 | Hochstufung | Stifel | Hold → Buy |
| 2024-03-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Herabstufung | Jefferies | Buy → Hold |
| 2024-01-03 | Herabstufung | Needham | Buy → Hold |
| 2023-11-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-07-18 | Herabstufung | Stifel | Buy → Hold |
| 2023-07-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-02-22 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-12-15 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-12-05 | Bestätigt | Needham | Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-15 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2022-09-14 | Eingeleitet | Loop Capital | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-02-18 | Hochstufung | Needham | Hold → Buy |
| 2022-02-16 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-10-12 | Fortgesetzt | Raymond James | Mkt Perform |
| 2020-09-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-04-20 | Herabstufung | Needham | Buy → Hold |
| 2020-03-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-05-07 | Bestätigt | Needham | Buy |
| 2019-04-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-03-13 | Bestätigt | Needham | Buy |
| 2018-12-19 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-09-14 | Eingeleitet | Needham | Buy |
| 2018-03-09 | Eingeleitet | Barclays | Overweight |
| 2017-08-14 | Hochstufung | BTIG Research | Neutral → Buy |
| 2017-04-04 | Bestätigt | Wedbush | Outperform |
| 2017-03-16 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-02-27 | Bestätigt | Wedbush | Outperform |
| 2017-02-13 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2016-08-04 | Bestätigt | Wedbush | Outperform |
| 2016-05-05 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-05-05 | Bestätigt | Wedbush | Outperform |
| 2016-01-06 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2015-08-05 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Masimo Corp Aktie (MASI) Neueste Nachrichten
ING Groep NV Buys New Position in Masimo Corporation $MASI - MarketBeat
Halper Sadeh LLC Encourages Masimo Corporation Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
Masimo sets Feb. 26 date to reveal 2025 earnings numbers - Stock Titan
Apple Again Pushes To Escape Masimo's $634M IP Verdict - Law360
Is Masimo Corporation impacted by rising ratesJuly 2025 Gainers & Real-Time Buy Signal Notifications - mfd.ru
Masimo Corporation (NASDAQ:MASI) Given Average Rating of "Hold" by Analysts - MarketBeat
Here's Why You Should Add Masimo Stock to Your Portfolio Now - Finviz
Masimo Investors' $34M Deal In Revenue Suit Gets Initial OK - Law360
Masimo’s $33.8 Million Investor Settlement Gets First Court Nod - Bloomberg Law News
Great Lakes Advisors LLC Sells 80,971 Shares of Masimo Corporation $MASI - MarketBeat
Masimo EVP Anand sells $2.56 million in shares By Investing.com - Investing.com South Africa
Masimo EVP Anand sells $2.56 million in shares - Investing.com
Owlet vs. Masimo: Which Medical Monitoring Stock Is the Better Buy? - TradingView
Why Masimo (MASI) is Poised to Beat Earnings Estimates Again - Finviz
Wall Street Analysts Think Masimo (MASI) Could Surge 31.06%: Read This Before Placing a Bet - Finviz
Strs Ohio Reduces Stock Position in Masimo Corporation $MASI - MarketBeat
Masimo wants Apple’s bid to erase a $634 million patent-infringement verdict overturned - MacTech.com
Masimo Fights Apple Bid to Undo $634 Million Apple Watch Verdict - Bloomberg Law News
Masimo to Sell Consumer Audio Business to HARMAN for $350 Million - rAVe [PUBS]
Massachusetts Financial Services Co. MA Boosts Holdings in Masimo Corporation $MASI - MarketBeat
Sumitomo Mitsui Trust Group Inc. Trims Stock Position in Masimo Corporation $MASI - MarketBeat
Masimo Stock Declines Despite Solid Preliminary Q4 Revenues - TradingView
Medical Device Connectivity Market is expected to generate a revenue of USD 13.4 Billion by 2032, Globally, at 23.40% CAGR: Verified Market Research® - GlobeNewswire Inc.
Masimo Releases Preliminary Q4 Results - ocbj.com
Masimo (NASDAQ:MASI) Updates Q4 2025 Earnings Guidance - MarketBeat
Masimo Corporation (NASDAQ:MASI) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Masimo Corp. Reports Strong Q3 2025 Growth - MSN
Why Masimo Corporation (3M4) stock is a strong analyst pickPrice Action & AI Based Buy and Sell Signals - ulpravda.ru
Why Masimo Corporation stock is trending among retail tradersDay Trade & Daily Stock Trend Reports - Улправда
How rising interest rates impact Masimo Corporation stockQuarterly Profit Summary & Advanced Swing Trade Entry Alerts - ulpravda.ru
Masimo’s Pediatric SpO2 Study With Philips Monitors: What Investors Should Watch - TipRanks
How to watch Masimo’s talk at the J.P. Morgan 2026 healthcare event - Stock Titan
Here's Why You Should Retain Masimo Stock in Your Portfolio Now - The Globe and Mail
Masimo (NASDAQ:MASI) Reaches New 12-Month LowHere's What Happened - MarketBeat
Masimo Corporation (MASI) Stock Analysis: Exploring a 44% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
Weekend Round-Up: TSMC's US Export Approval, Masimo's Quality Concerns And Apple's Vision Pro Woes - Benzinga
MASI (Masimo) Net Interest Income : $-34 Mil (TTM As of Sep. 2025) - GuruFocus
Apple's Vision Pro Production Plans, Masimo's Quality Score Declines Despite Patent Win, And More: This Week In Appleverse - Benzinga
MASI (Masimo) Total Equity : $810 Mil (As of Sep. 2025) - GuruFocus
MASI Stock Price, Forecast & Analysis | MASIMO CORP (NASDAQ:MASI) - Chartmill
Apple's Rival Masimo Tumbles In Quality Despite $634 Million Patent Win Over iPhone-Maker - Benzinga
Masimo Corporation $MASI Shares Sold by Voya Investment Management LLC - MarketBeat
Wells Fargo Maintains Overweight on Masimo (MASI) Following Investor Day Confidence In Long-Range Revenue Targets - Finviz
Masimo Corporation stock hits 52-week low at 131.47 USD By Investing.com - Investing.com South Africa
Finanzdaten der Masimo Corp-Aktie (MASI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Masimo Corp-Aktie (MASI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sampath Anand | EVP, Ops & Clinical Research |
Jan 28 '26 |
Option Exercise |
37.84 |
30,000 |
1,135,200 |
59,589 |
| Sampath Anand | EVP, Ops & Clinical Research |
Jan 28 '26 |
Sale |
136.81 |
18,680 |
2,555,570 |
40,909 |
1.33%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):